Literature DB >> 9112588

Restless legs and periodic leg movements in sleep syndromes.

T C Wetter1, T Pollmächer.   

Abstract

Restless legs syndrome (RLS) is a common sensorimotor disorder with an estimated prevalence of between 1% and 5%. The symptomatology is characterized by unpleasant sensations experienced predominantly in the legs and rarely in the arms. The symptoms occur only at rest and become more pronounced in the evening or at night. In addition, the patients suffer from a strong urge to move the limbs, typically manifest as walking around, which leads to complete but only temporary relief of the symptoms. Most of the patients with RLS have periodic leg movements (PLMS) during sleep and relaxed wakefulness that are characterized by repetitive flexions of the extremities. PLMS can occur as an isolated phenomenon, but often they occur together with other sleep disorders including RLS, narcolepsy, sleep apnoea syndrome or REM sleep behaviour disorder. In all these disorders, PLMS, contribute considerably to disturbed sleep, as the movements may lead to brief arousals or repeated full awakenings. The aetiology of RLS and PLMS is unknown. It is hypothesized that periodic leg movements result from a suprasegmental disinhibition of descending inhibitory pathways. Based on the efficacy of the drugs listed below, the dopaminergic, adrenergic and opiate systems are thought to play a major role in the pathogenesis of RLS/PLMS. Since the cause is unclear, therapy of RLS and PLMS remains symptomatic except for some secondary forms. Studies on the pharmacological treatment of RLS have shown the efficacy of levodopa, dopamine agonists, benzodiazepines, opioids, clonidine and carbamazepine. With regard to the drug treatment of PLMS in other sleep disorders including their isolated occurrence, indications and efficacy have been poorly defined until now.

Entities:  

Mesh:

Year:  1997        PMID: 9112588     DOI: 10.1007/bf03160570

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  80 in total

1.  Lithium-aggravated nocturnal myoclonus and restless legs syndrome.

Authors:  E M Heiman; M Christie
Journal:  Am J Psychiatry       Date:  1986-09       Impact factor: 18.112

2.  Some periodic phenomena arising during drowsiness and sleep in man.

Authors:  E Lugaresi; G Coccagna; M Mantovani; R Lebrun
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1972-06

3.  Response to opioids in three patients with restless legs syndrome.

Authors:  P T Trzepacz; E J Violette; M J Sateia
Journal:  Am J Psychiatry       Date:  1984-08       Impact factor: 18.112

4.  Dopaminergic treatment of restless legs and rebound phenomenon.

Authors:  C Guilleminault; M Cetel; P Philip
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

5.  Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

Authors:  C Brodeur; J Montplaisir; R Godbout; R Marinier
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

6.  Bereitschaftspotential in idiopathic and symptomatic restless legs syndrome.

Authors:  C Trenkwalder; S F Bucher; W H Oertel; D Proeckl; H Plendl; W Paulus
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1993-04

7.  Triazolam diminishes daytime sleepiness and sleep fragmentation in patients with periodic leg movements in sleep.

Authors:  K Doghramji; C P Browman; J R Gaddy; J K Walsh
Journal:  J Clin Psychopharmacol       Date:  1991-10       Impact factor: 3.153

8.  Effects of bromocriptine on periodic limb movements in human narcolepsy.

Authors:  D B Boivin; D Lorrain; J Montplaisir
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

9.  Effect of L-dopa on periodic movements in sleep in narcolepsy.

Authors:  M A Bédard; J Montplaisir; R Godbout
Journal:  Eur Neurol       Date:  1987       Impact factor: 1.710

10.  Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.

Authors:  C von Scheele; V Kempi
Journal:  Arch Neurol       Date:  1990-11
View more
  12 in total

1.  Neurodegenerative Disease and REM Behavior Disorder.

Authors:  Raman Malhotra; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2012-10       Impact factor: 3.598

2.  Sleep Dysfunction in Alzheimer's Disease and Other Dementias.

Authors:  Susan M. McCurry; Sonia Ancoli-Israel
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

Review 3.  Sleep disorders in the elderly.

Authors:  R Asplund
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

4.  The higher prevalence of non-right handers among patients with restless leg syndrome.

Authors:  Shadi Ghourchian; Parviz Bahrami
Journal:  Neurol Sci       Date:  2014-07-02       Impact factor: 3.307

Review 5.  Restless legs syndrome and Parkinson's disease: is there an etiologic link?

Authors:  Eng-King Tan
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

6.  Linking restless legs syndrome with Parkinson's disease: clinical, imaging and genetic evidence.

Authors:  Tasneem Peeraully; Eng-King Tan
Journal:  Transl Neurodegener       Date:  2012-02-27       Impact factor: 8.014

Review 7.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Time structure analysis of leg movements during sleep in REM sleep behavior disorder.

Authors:  Mauro Manconi; Raffaele Ferri; Marco Zucconi; Maria Livia Fantini; Giuseppe Plazzi; Luigi Ferini-Strambi
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

9.  The effect of selenium administration on restless leg syndrome treatment.

Authors:  A G Rahimdel; P Ayatollahi; A Zeinali; N Mehrabanian; A Mellat-Ardekani
Journal:  Iran Red Crescent Med J       Date:  2012-01-01       Impact factor: 0.611

10.  Differential Dopamine D1 and D3 Receptor Modulation and Expression in the Spinal Cord of Two Mouse Models of Restless Legs Syndrome.

Authors:  Samantha Meneely; Mai-Lynne Dinkins; Miki Kassai; Shangru Lyu; Yuning Liu; Chien-Te Lin; Kori Brewer; Yuqing Li; Stefan Clemens
Journal:  Front Behav Neurosci       Date:  2018-09-04       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.